Schrödinger, Inc. (SDGR)
Summary
Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
Schrödinger, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 42 | $825.88 | $643.44 | -$182.44 | -22.09% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 95 | $1,698.6 | $1,455.4 | -$243.2 | -14.32% |
 Farallon Capital Farallon Capital Management LLC | 17,000 | $342,040 | $260,440 | -$81,600 | -23.86% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 15,619 | $300,182.08 | $239,283.08 | -$60,899 | -20.29% |
| BG Bart Gancher Intech Investment Management LLC | 12,227 | $241,360.98 | $187,317.64 | -$54,043.34 | -22.39% |
Schrödinger, Inc. (SDGR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Schrödinger, Inc. ever had a stock split?
Schrödinger, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Ramy Farid CEO | NASDAQ (NGS) Exchange | 80810D103 CUSIP |
| US Country | 847 Employees | - Last Dividend | - Last Split | 6 Feb 2020 IPO Date |
Overview
Schrödinger, Inc. is a pioneering company that develops a sophisticated computational platform grounded in physics, which is designed for the discovery of novel molecules applicable in both drug development and materials science. Since its inception in 1990, Schrödinger has been operating out of New York, New York, undertaking ambitious endeavors in molecular discovery across two primary segments: Software and Drug Discovery. The Software segment is dedicated to revolutionizing molecular discovery in the life sciences and materials science industries through its proprietary software solutions. On the flip side, the Drug Discovery segment is committed to advancing a broad spectrum of preclinical and clinical programs either internally or in partnership with other entities. Catering to a global clientele, Schrödinger serves a wide range of industries, including biopharmaceutical firms, industrial companies, academic institutions, and government laboratories around the world.
Products and Services
- Software Licensing
Under the Software segment, Schrödinger offers licenses for its cutting-edge software designed to significantly enhance the process of molecular discovery. This software is strategically crafted for both life sciences and materials science sectors, streamlining and expediting the research and development process for a myriad of applications.
- Drug Discovery
In the Drug Discovery segment, Schrödinger emphasizes the development of a diversified portfolio of drug candidates. This portfolio spans various stages of the discovery and development process, ranging from preclinical studies to clinical trials. The company not only works on these programs internally but also collaborates with external partners to leverage collective expertise and resources, thereby fostering innovation and accelerating the journey of potential drugs from the laboratory to the marketplace.
